The role of Th1/Th2 disbalanced immune response in the determination of clinical features of autoimmune diabetes mellitus

Aim.
To elucidate the role of Th1/Th2 polarization of immune response in LADA patients in the realization of the clinical phenotype of the disease.
Materials and methods.
70 patients aged 21-61 (mean 41.3?1.0 yr) with DM diagnosed based on WHO criteria (1999). Groups 1 and 2 included 13 DM1and 57 DM2 patients (34.6?7.2 and 43.6?7.6 yr respectively). 27 DM2 patients (41.2?1.6 yr) presumably had LADA (P. Zimmet's criteria).Serum anti-GAD65, ICA, and IAA antibodies along with C-peptide were measured in fasting sera and 120 min after GTT by solid phase immunoenzymeassays following manufacturer's instructions with the use of a photometer for Multiscan EX microplates (ThermoLabSystems, Finland) at405 nm (for GAG and ICA) and 450 nm (for IAA and C-peptide). GAD, IAA, and C-peptides levels were calculated automatically from calibrationcurves. Mononuclear leukocytes were isolated by centrifugation in the ficoll-verographin density gradient. The cells thus obtained were resuspendedin the complete nutritient medium reducing their concentration to 2.0x10^6/ml. Phytohemagglutinin (Difco, Germany) was added (10 mcg/1 ml) tothe samples to stimulate mononuclear leukocytes; cell suspensions were further incubated for 24 hr. Initial and PGA-induced levels of IL-2, 4, 10 insupernatants of cell cultures were measured by solid phase immunoassay at 450 nm.
Results.
At least one type of autoantibodies (GAD, ICA or IAA) was identified in 24.3% of all DM patients (17/70) and in 18% of the DM2 patients(10/57). The level of anti-GAD and ICA ABs and percentage of AB-positive patients were higher in the LADA group while that of anti-IAA ABs amongDM1 patients without LADA. Two AB types at a time were found in 17% (4/23) of the patients with autoimmune DM in the absence of significantdifference between LADA and DM1. Patients with LADA had a significantly lower basal C-peptide level than DM2 patients. The was a tendencytoward lower level of stimulated C-peptide secretion in LADA patients compared with DM2 ones. It suggests impairment of beta-cell secretory functionaffected by the autoimmune process. We observed enhanced basal production of IFN-y by blood mononuclear leukocytes in all DM patients in theabsence of significant difference between the groups. Mitogen-activated production in all CD patients was lower than normal without inter-groupdifferences. Patients with DM2 had the inverted type of IL-2 secretion unlike those with autoimmune diabetes. In both cases it was significantly differentfrom normal values. There was a tendency toward higher basal production of IL-4 by mononuclear leukocytes in LADA and DM2 comparedwith CD1 which reflects pathogenetic peculiarities of beta-cell function in LADA differing from those in DM1 and responsible for slower impairment ofbeta-cell function in this condition. Basal and PGA- induced production of IL-10 was higher in LADA and DM2 than in DM1. It suggests enhancedsuppressor activity of leukocytes that may protect beta-cells from autoimmune destruction and determines gradual development of clinical symptoms ofinsulin deficiency. In contrast, low production of IL-10 in DM1 gives evidence of polarization of the immune response.
Conclusion.
The loss of functional parenchyma and manifestation of insulin deficiency in LADA occur at a relatively low rate due to the peculiarcharacter of cytokine-mediated cell interactions. It suggests the necessity of an active and careful diagnostic strategy with the use of immunologicalmethods for examination of elder patients presenting with a variety of pathogenetic variants of DM.

latent autoimmune diabetes, mellitus in adults, type 1 diabetes, cytokines, immunopathogenesis

1. Wild S., Roglic G., Green A., Sicree R., King H. Global Prevalence of Diabetes // Diabetes Care. - 2004. - V 27. - № 5. - P. 1047-1053.

2. Дедов И. И., Кураева Т. Л., Петеркова В. А. Генетические факторы в развитии сахарного диабета в России // Молекулярная медицина. - 2003. - № 1. - С. 31-37.

3. Кононенко И. В., Прокофьев С.А., Смирнова О. М. Функциональное состояние ƒ-клеток, иммунологические и клинико-биохимические характеристики у больных с медленно прогрессирующим ауто- иммунным диабетом взрослых // Проблемы эндокринологии. - 2004. - Т. 50. - № 1. - С. 18-22.

4. Groop L., Bottazzo G.F., Doniach D. Islet cell antibodies identify latent type 1 diabetes in patient aged 35-75 years at diagnosis // Diabetes. - 1986. - V. 35. - P.237-241.

5. Смирнова О. М., Кононенко И. В., Дедов И. И. Аутоиммунный латентный сахарный диабет у взрослых // Проблемы эндокринологии. - 2008. - Т. 54. - № 2. - С. 1-7.

6. Diabetes Control and Complication Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complication in insulin-dependent diabetes mellitus // The New England Journal of Medicine. - 1993. - V. 329. - P. 977-986.

7. Palmer J. P., Fleming G. A., Greenbaum C. J. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function : report of an ADA workshop // Diabetes. - 2004. - V. 53. - P. 250-264.

8. Moriawaki M., Iton N., Miyagawa J.The development of IDDM in the BB-rats // Diabetologia. - 1999. - Vol. 42. - № 11. - P.1332-1340.

9. Suarez-Pinzon W., Sorensen O., Bleacley R.C. Beta-cell destruction in NOD mice correlates with Fas (CD95) expression on beta-cells and proinflammatory cytokine expression in islets // Diabetes. - 1999. - Vol. 48. - № 1. - P.21-28.

10. Toyoda H., Formby B. Contribution of T cells to the development of autoimmune diabetes in the NOD mouse model // Bioessays. - 1998. - Vol. 20, 39. - P. 750-757.

11. Green E.A., Flavell R.A. Tumor necrosis factor-alpha and the progression of diabetes in non-obese diabetic mice // Immunol. Rev. - 1999. - Vol. 169. - P. 11-22.

12. Hosszufalusi N., Vatay A., Rajczy K. Similar genetic features and different islet cell autoantibody pattern of latent autoimmune diabetes in adults (LADA) compared with adult-onset type 1 diabetes with rapid progression // Diabetes Care. - 2003. - Vol. 26. - P. 452-7.

13. Zimmet P.Z., Turner R., McCarty D. Crucial points at diagnosis. Type 2 diabetes or slow type 1 diabetes // Diabetes Care. - 1999. - Vol. 22. - № 2. - P. 59-64.

14. Pavlovic D., Vandewinkel M., Vanderauwera B. Effect of interferon-gamma and glucose on major histocompatibility complex class I and class II expression by pancreatic beta- and non-beta-cells.// J. Clin. Endocrinol. - 1997. Vol. 82. - № 7. - P. 2329-2336.

15. Ahren B., Havel P.J. Leptin inhibits insulin secretion induced by cellular cAMP in a pancreatic B cell line (INS-1 cells) // Am. J. Physiol. - 1999. - Vol. 277. - P. R959-R966.

16. Rabinovitch A. An update on cytokines in the pathogenesis of insulin-dependent diabetes mellitus // Diabet. Metab. - 1998. - Vol. 14. - №2. - P. 129-151.

17. Rabinovitch A., Suarez-Pinzon W.L., Sorensen O. IFN-gamma gene expression in pancreatic islet-infiltrating mononuclear cells correlates with autoimmune diabetes in nonobese diabetic mice // J. Immunol. - 1995. - Vol. 154. - № 9. - P. 4874-4882.

18. Bruun C., Heding P.E., Ronn S.G. Inhibitory effects of suppressor of cytokine signaling-3 on tumor necrosis factor-alpha induced signaling in pancreatic beta cells // Diabetologia. - 2005. - Vol. 48, suppl. 1. A. 181.

19. Chen M., Yang Z.D., Zmith K.M. Activation of 12-lipoxygenase in proinflammatory cytokine-mediated beta cell toxicity // Diabetologia. - 2005. - Vol. 43. - № 3. - P. 486-495.

20. Storling I., Binzer J., Andersson A.K. Nitric oxide caused activation of JNK suppression of Akt in insulin-secreating cells // Diabetologia. - 2005. - Vol. 48, (suppl.1). A38.

21. Storling I., Binzer J., Andersson A.K. Nitric oxide contributes to cytokineinduced apoptosis in pancreatic beta cells via potentiation of JNK activity and inhibition of Akt // Diabetologia. - 2005. - Vol. 48. - № 10. - P. 2039-2050.

22. Kukreja A., Cost G., Marker J. Multiple immunoregulatory defects in type-1 diabetes // J. Clin. Invest. - 2002. - Vol. 109. - № 1. - P. 131-140.

23. Kukreja A., Maclaren N. K. Autoimmunity and diabetes // J. Clin. Endocrinol. Metab. - 1999. - V. 84. - № 12. - P. 4371-4378.

24. Avanzini M.A., Ciardelli L., Lenta E. IFN-gamma low production capacity in type 1 diabetes mellitus patients at onset of disease // Exp. Clin. Endocrinol. Diabetes. - 2005. - Vol. 113. - № 6. - P. 313-317.

25. Rapaport M.J., Bistritzer T., Aharoni D. Th1/Th2 cytokine secretion of first degree relatives of T1DM patients // Cytokine. - 2005. - Vol. 30. - № 5. - P. 219-227.

26. Citarella R., Richiusa P., Mattina A. Different Th1/Th2 cytokine expression in type 1 diabetes mellitus patients (T1DM) alone or associated with autoimmune thyroid disease (AITD) // Diabetologia. - 2004. - Vol. 47 (Suppl. 1): A188.

27. Tomoda T., Kurashige T., Taniguchi T. Imbalance of the interleukin 2 system in children with IDDM // Diabetologia. - 1994. - Vol. 37. - № 5. - P. 476-482.

28. Попова В. В., Мельниченко С. В., Малиновская Т. Н. Содержание цитокинов в крови в доклиническую и раннюю клиническую стадии развития сахарного диабета у детей // Проблеми ендокринної патології. - 2004. - T. 2. - C. 53-59.

29. Karlsson M. G., Lawesson S.S., Ludvigsson J. Th1-like dominance high risk first-degree relatives of type I diabetic patients // Diabetologia. - 2000. - V. 43, № 6. - P. 742-749.

30. Leech N. J., Elsegood K. A., Narendran P. T helper 1profile of recently activated circulating T cells in type 1diabetes // Diabetologia. - 1999. - V. 42, Suppl. 1. - A 316.

31. Bonato V., Dionisi S., Vendrame F. Oral probiotic administration in the NOD mouse induces systemic and islet IL-10 production and down regulates pancreatic expression of proinflammatory cytokine and chemokines // Diabetologia. - 2005. - V. 48, Suppl. 1. - А 193.

32. Chang Y., Piao S. L., Gao S. Regulatory effects of micronutrient complex on the expression of Th1and Th2 cytokines in diabetic C57BL mice // Wei Sheng Yan Jiu. - 2005. - V. 34. - № 1. - P. 64-66.